Hemcheck has finalised the verification phase regarding the new product for the blood gas market and is now entering a final validation phase, where usability and performance will be evaluated in a user environment. This is the last important phase before a CE-marking can be achieved, which is needed for the product to be sold on the European market.

The new product is called the bgs-Test (bgs stand for blood gas syringe) and is a hemolysis test which can receive a significantly larger amount of blood compared to current tests and in addition function as an airtight cap while allowing for air ventilation of syringes. This allows for integration of hemolysis control in patient near tests such as blood gas analysis, including improved adaptation to current workflows. It also expands Hemcheck’s addressable market since the bgs-Test can be used in combination with more types of syringes. Lastly, it creates even better conditions for combining our product offering with other companies’ offers.

– There is a lot of work behind reaching this milestone with the bgs-Test and we look forward to the last phase, taking the product to CE-marking. The objective is to finalise the required work before end of year and that the CE-marking will be done early January. We also continue working with the patent applications linked to the product, which is an important part of how we build value in the company, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.